Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 571 to 580 of 874 total matches.
Rabeprazole
The Medical Letter on Drugs and Therapeutics • Nov 19, 1999 (Issue 1066)
. Headache, nausea, abdominal pain, constipation, flatulence and diarrhea can occur. Myalgias, rash ...
Rabeprazole, a benzimidazole proton pump inhibitor similar to omeprazole and lansoprazole, has been approved by the FDA for treatment of duodenal ulcers, healing and maintenance treatment of erosive or ulcerative gastroesophageal reflux disease, and for long-term treatment of chronic hypersecretory conditions, including Zollinger-Ellison syndrome
A New Long-acting Methylphenidate (Concerta)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2000 (Issue 1086)
methylphenidate
t.i.d. and more effective than placebo.
ADVERSE EFFECTS — Headache, abdominal pain, anorexia ...
Methylphenidate (Ritalin, and others) is now available in a new extended-release formulation (Concerta--Alza) for treatment of attention deficit/hyperactivity disorder (ADHD).
Substituting For Cerivastatin (Baycol)
The Medical Letter on Drugs and Therapeutics • Sep 17, 2001 (Issue 1113)
be advised to promptly report unexplained muscle pain, tenderness or weakness, especially if they
are taking ...
Full-page newspaper advertisements are urging patients with high cholesterol levels who are stopping Baycol (cerivastatin) to ask their doctors about Pravachol (pravastatin), Lipitor (atorvastatin), Zocor (simvastatin) or Lescol (fluvastatin). Some advertisements come with a coupon for free medication. Lovastatin, which is available generically, has not appeared in similar advertisements. Cerivastatin was withdrawn from the market on August 8 because of post-marketing reports of 31 cases of fatal rhabdomyolysis.
Another long-acting Methylphenidate (Metadate CD)
The Medical Letter on Drugs and Therapeutics • Oct 01, 2001 (Issue 1114)
EFFECTS — As with other methylphenidate formulations, anorexia, insomnia,
headache and abdominal pain ...
Methylphenidate is now available in a new extended-release formulation (Metadate CD - Celltech) for treatment of attention deficit/hyperactivity disorder (ADHD). The new product, which is a Schedule II controlled substance, is being advertised directly to consumers.
Once-a-week Risedronate (Actonel)
The Medical Letter on Drugs and Therapeutics • Oct 14, 2002 (Issue 1141)
, abdominal pain and diarrhea, and oral bioavailability is limited ( ...
A once-weekly 35-mg oral formulation of the bisphosphonate risedronate (Actonel) has been approved by the FDA for prevention and treatment of postmenopausal osteoporosis. A once-weekly formulation of alendronate (Fosamax) was approved last year (Medical Letter 2001; 43:26). Bisphosphonates bind to the mineral surface of bone and decrease osteoclast activity, inhibiting the resorption phase of the bone turnover cycle. These drugs are not metabolized and remain bound to bone for several weeks.
Indications for an Implantable Cardioverter Defibrillator
The Medical Letter on Drugs and Therapeutics • Nov 25, 2002 (Issue 1144)
% of patients in one prospective study, have included dislodgement, seroma, hematoma, infection, pain ...
There is no longer any doubt that an implantable cardioverter defibrillator (ICD) can reliably terminate most life-threatening ventricular tachyarrhythmias. The remaining question is who should get one. Guidelines prepared by an American College of Cardiology/American Heart Association task force have recently been published (G Gregoratos et al, Circulation 2002; 106:2145).
Emergency Contraception OTC
The Medical Letter on Drugs and Therapeutics • Feb 02, 2004 (Issue 1175)
with levonorgestrel, but less frequently
than with the estrogen-progestin combination. Headache, abdominal pain ...
An FDA Advisory Committee has recommended over-the-counter (OTC) marketing of Plan B (Barr), an emergency contraceptive "pill pack" that contains two 0.75-mg tablets of levonorgestrel to be taken 12 hours apart (Medical Letter 2000; 42:10). Plan B is one of two FDA-approved products for this indication. The Preven Emergency Contraceptive Kit (Medical Letter, 40:102, 1998) includes four tablets, each containing 0.25 mg of levonorgestrel and 50 ╡g of ethinyl estradiol; these are taken 2 at a time 12 hours apart (the "Yuzpe regimen") and are available only by...
Pemetrexed (Alimta) for Mesothelioma
The Medical Letter on Drugs and Therapeutics • Apr 12, 2004 (Issue 1180)
; 21:2636). Patients on the combination also showed improvement in pain, shortness of breath ...
The combination of pemetrexed (Alimta - Lilly) and cisplatin is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma. This uncommon malignancy, which has been linked to asbestos exposure, was previously considered unresponsive to chemotherapy, with a median survival of 6-8 months from diagnosis (VW Rusch, J Clin Oncol 2003; 21:2629).
Pegloticase (Krystexxa) for Treatment of Refractory Gout
The Medical Letter on Drugs and Therapeutics • Feb 07, 2011 (Issue 1357)
(urticaria, dyspnea, chest pain/discomfort, erythema
and pruritus) occurred in 26% of patients treated ...
Pegloticase (Krystexxa – Savient), a PEGylated urate oxidase enzyme, has been approved by the FDA for intravenous (IV) treatment of chronic symptomatic gout in adults who have not responded to maximum doses of a xanthine oxidase inhibitor, such as allopurinol (Zyloprim, and others). Pegloticase is the second new drug approved for gout in more than 40 years; a new xanthine oxidase inhibitor, febuxostat (Uloric), was approved in 2009.
Drugs for Urinary Tract Infections
The Medical Letter on Drugs and Therapeutics • Jul 23, 2012 (Issue 1395)
tromethamine Diarrhea, nausea, headache,
vaginitis, dizziness abdominal
pain, asthenia, rash
Ciprofloxacin ...
The most recent guidelines from the Infectious
Diseases Society of America (IDSA) and its European
counterpart on the choice of antimicrobials for treatment
of uncomplicated urinary tract infections (UTIs) in
non-pregnant women focus on the unnecessary use of
fluoroquinolones to treat uropathogens that are
increasingly becoming resistant to them. Resistance
of Escherichia coli to ciprofloxacin in the US has
increased from 3% in 2000 to 17.1% in 2010.